Phytonutrients: Sources, bioavailability, interaction with gut microbiota, and their impacts on human health

Juntao Kan¹, Feng Wu¹, Feijie Wang¹, Jianheng Zheng¹, Junrui Cheng³, Yuan Li², Yuexin Yang*⁴ and Jun Du¹*⁴

¹Nutrilite Health Institute, Shanghai, China, ²Sequanta Technologies Co., Ltd., Shanghai, China, ³Department of Molecular and Structural Biochemistry, North Carolina State University, Kannapolis, NC, United States, ⁴Chinese Center for Disease Control and Prevention, National Institute for Nutrition and Health, Beijing, China

Phytonutrients are natural bioactive components present in the daily diet that can exert a positive impact on human health. Studies have shown that phytonutrients may act as antioxidants and improve metabolism after being ingested, which help to regulate physiological processes and prevent metabolic disorders and diseases. However, their efficacy is limited by their low bioavailability. The gut microbiota is symbiotic with humans and its abundance and profile are related to most diseases. Interestingly, studies have shown that the gut microbiota is associated with the metabolism of phytonutrients by converting them into small molecules that can be absorbed by the body, thereby enhancing their bioavailability. Furthermore, phytonutrients can modulate the composition of the gut microbiota, and therefore improve the host’s health. Here, we focus on uncovering the mechanisms by which phytonutrients and gut microbiota play roles in health, and the interrelationships between phytonutrients and gut microbiota were summarized. We also reviewed the studies that reported the efficacy of phytonutrients in human health and the future directions.

KEYWORDS
phytonutrients, gut microbiota, metabolism, health outcomes, bioavailability

Introduction

Nutrients play an essential role in maintaining the regular functions in the body. Their basic functions include providing energy, contributing to body structure, and regulating chemical processes. Carbohydrates, lipids, protein, vitamins, and minerals are the major nutrients in food (1, 2). There are also certain physiologically active compounds known as “phytonutrients” that play a crucial role in human health. Previous studies have shown that phytonutrients are effective in preventing and mitigating a variety of diseases and physiological disorders, thus imposing a tremendous impact on the medical and health care system. Common phytonutrients include polyphenols, phytosterols, saponins, and carotenoids. Well-documented phytonutrients, such as catechins, curcumin, anthocyanins, quercetin and chlorogenic acid, can be easily...
ingested from diets, and many studies have demonstrated their role in anti-cancer, neuroprotection, anti-aging, treatment of metabolic disorders, and other diseases (3–5). For example, curcumin and chlorogenic acid have been implicated in alleviating fat accumulation, high cholesterol, and metabolic disorders by affecting protein synthesis pathways and modulating immune responses (6, 7). In general, due to people's pursuit of a healthy diet, there has been a growing focus on natural products in recent years (8), and phytonutrients hold a great promise in healthcare and clinical therapy thanks to their beneficial effects (9, 10).

Understanding the metabolism and pharmacokinetics of phytonutrients may facilitate the application of phytopharmaceuticals to mitigate various diseases. Limited by phytonutrients and individual differences in digestive capacity, membrane transporters and metabolic enzymes, only a small part of phytonutrients can be directly absorbed by the human body after oral administration, and metabolism is mainly carried out in the liver and intestine (11). In the liver, phytonutrients undergo oxidation, demethylation, and hydrolysis reactions in phase I, and then combine with endogenous binders in phase II to form small molecules to facilitate absorption. Despite a low inaccessibility in the upper gastrointestinal tract, the bioavailability of phytonutrients can be greatly enhanced with the participation of gut microbiota in the lower gastrointestinal tract (12). Poorly absorbed phytochemicals undergo microbiota-mediated biotransformation such as cleavage, demethylation, dihydroxylation, deglycosylation, and are able to produce metabolites with higher bioavailability and bioactivity (13, 14). For example, the bioavailability of cyanidin-3-glucoside is only 0.02%, while the microbial degradation product of cyanidin-3-glucoside, 3,4-dihydroxybenzoic acid, has a bioavailability of 44% (15).

Gut microbiota is a complex ecological community comprising trillions of bacteria that live in the human gut and develop a mutually beneficial symbiosis (16). Gut microbes assist in human digestion by decomposing chemicals that the human gut is unable to degrade on its own (17). Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria are the most common bacteria genera in the human gut microbiota (18). They can integrate brain and gastrointestinal functions, such as intestinal movement, appetite and weight, through the microbiota-gut-brain axis (19), and then affect normal physiology and disease susceptibility through their collective metabolic activity and host interactions (20–23). Gut microbiota are not static, instead, they have been in a dynamic process throughout the lifespan (24).

The relationship between phytonutrients and the human gut microbiota is a two-way complex interaction. Phytonutrients are absorbed first to alter the composition of the gut microbiota which includes inhibiting pathogens and promoting the growth of beneficial bacteria (5), and then to influence the production of their metabolites, which would further modify the intestinal environment by inhibiting the production of harmful compounds such as indole, lipopolysaccharide, and hydrogen sulfide (25). Some polyphenols, such as those found in green and black tea, may inhibit the growth of detrimental bacteria such as Helicobacter pylori, Listeria monocytogenes, Staphylococcus aureus, Escherichia coli, Salmonella typhimurium, and Pseudomonas aeruginosa (26–29). In the meantime, microbial metabolites such as short chain fatty acids and other bioactive components fermented/degraded by gut microbiota not only provide essential materials and energy for the growth of gut microbes, but also can target multiple pathways in intestine, liver, and pancreas, resulting in improvements in gut health (8, 30). For example, chlorogenic acid and its related compounds can be metabolized in the gut by the resident microbiota, which are responsible for the release of caffeic acid and further metabolism, producing phenylpropionic, phenylacetic, and benzoic acid derivatives that are then absorbed into the circulatory system for further actions (7, 31).

Overall, the relationship between phytonutrients and human health is established through the metabolic function of the human digestive system, mainly through the participation of gut microbiota (32, 33). The gut acts as an important sensory organ capable of detecting, transmitting, integrating, and responding to signals from the internal and external environment, thereby triggering responses. Cascades of communication along the gut-brain axis are associated with inflammatory responses and immune homeostasis (34). For example, Ohno et al. reported that curcumin supplementation modulated the composition of gram-negative bacilli and subsequently strengthened intestinal barrier and regulated the metabolic functions of gut microbes, such as bile acid biosynthesis and arachidonic acid metabolism (35). The purpose of regulating physiological processes and treating diseases is achieved through immunomodulation and anti-inflammatory, anti-oxidative stress, and inhibition of various enzymatic functions (6, 36), showing a complete chain of action of phytonutrients. Accumulating evidence shows that different phytonutrients may impact human health through different modes of action and targets (37–42).

In conclusion, as the natural products from plants, phytonutrients have shown unique diversity and safety. Phytonutrients are involved in various physiological processes and may prevent/mitigate disease pathogenesis through the gut microbiota, which are closely linked with an individual's overall health (Figure 1). The complex and dynamic interactions between phytonutrients and gut microbiota have become a research hotspot. This review summarizes the sources, metabolic processes of five phytonutrients including catechins, curcumin, quercetin, anthocyanins and chlorogenic acid, and their interactions with the gut microbiota. In addition, the influence of these impacts on metabolism and the future directions of phytonutrient-related studies are portrayed in detail.
Catechins and gut microbiota

Sources and chemical structures of catechins

As a member of the flavan-3-ol polyphenol family, catechins are widely distributed in a range of dietary sources, such as tea, cocoa, apple, and kiwi fruit. Catechins are extremely abundant in polyphenol-rich green tea and its extracts, accounting for approximately one-third of the solids in brewed green tea. Catechins include four major items, namely epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin (EC), and epicatechin-3-gallate (ECG), among which EGCG is the most abundant and has the highest biological activity. The presence of certain chemical structures like catechol group and pyrogalol group in these compounds provide them with strong antioxidant properties and biological activity. Numerous studies have demonstrated the health effects of catechins, including anti-inflammatory, antimicrobial, immunomodulatory, and neuroprotective effects.

Bioavailability and metabolism of catechins

The bioavailability of catechins in the human body is extremely poor. After oral administration, only a small fraction of catechins is bioavailable, and transported to the liver via the portal vein, where phase II enzymes convert them into methyl, glucuronide, and sulfate derivatives. In fact, only around 14% EGC, 32% EC, and 0.1% EGCG are accessible upon oral intake. Approximately two-thirds of catechins reach the colon where catechins are degraded by microbial enzymes into a range of metabolites, followed by being released into the enterohepatic or systemic circulation to perform diverse physiological roles. There is evidence indicating that the phase II metabolism of EC may occur in enterocytes, and the metabolites (mainly sulfated conjugates) of EC were eliminated by efflux back to the intestinal lumen, which was much higher than the elimination via bile.

Interactions between catechins and gut microbiota

Biotransformation of catechins into their metabolites is mainly dependent on the gut microbiota. The gut microbiota's vast gene pool transforms the colon into a bioreactor with immense catechin metabolic capacity. The gut microbiota can execute glycosidic connections, C-ring fission, and degradation of the heterocyclic structures of catechins, resulting in smaller compounds such as phenylvalerolactones and phenylvaleric acids. These newly produced microbial metabolites may then be absorbed.
across the colon epithelium and eventually enter the systemic blood circulation (41). The metabolites of catechins produced by microbial biotransformation may even outperform the parent molecules in terms of biological activity (60). The relevant process is summarized in Figure 3.

**Metabolism of catechins by gut microbiota**

Catechins are metabolized by the gut microbiota to facilitate absorption, and the degradation pathway has been documented in various studies. The transformations can be split into three major processes: (I) galloyl ester hydrolysis, (II) C-ring opening, and (III) lactonization, decarboxylation, dehydroxylation, and oxidation processes to further modify the reaction products (53, 61, 62). Regarding galloylated catechins (ECG and EGCG), the microbial metabolism begins with galloyl ester hydrolysis by microbial esterases, which produces gallic acid. The C-ring of the catechin residue is opened after degalloylation, resulting in diphenylpropan-2-ol, which is then transformed into valerolactone, resulting in the formation of hydroxyphenylvaleric acids and/or 4-hydroxyphenylvaleric acids. Meanwhile, dehydroxylation of these hydroxylated phenolic acids at the original B-rings may occur, yielding a variety of simpler phenolic acids. The principal reaction products from catechins for intestinal absorption are valerolactone and phenolic acids (63), which can be easily absorbed by the large intestine and then undergo phase I and phase II metabolism, distribution and excretion (53).

Kutschera et al. reported that two bacterial strains, *Flavonifractor plautii* and *Eggerthella lenta*, could biotransform dietary catechins into hydroxyvaleric acid and valerolactone metabolites (64). To further understand the underlying mechanisms of the gut microbiota in modulating the effects of catechins on health, more research is required to determine the microbiota’s functional guild and characterization (65).
Modulation of gut microbiota by catechins

Catechins are antibacterial compounds that are effective against foodborne and other harmful microorganisms. The most widely acknowledged mechanism for catechins’ antibacterial action is their capacity to disrupting membranes. EGCG can attach directly to the exposed peptidoglycan layer of Gram-positive bacteria, causing cross-links in the peptidoglycan to be cleaved. When the peptidoglycan layer is damaged, its protective impact is diminished and permeability increases, resulting in bacterial demise (53, 66).

Several in vitro studies suggest that catechins may have prebiotic effects by selectively improving the growth of beneficial gut microbiota (28, 67). Green tea catechins have been shown to boost the populations of beneficial bacteria, such as *Bifidobacterium* spp. and *Lactobacillus*, while suppress the harmful bacteria including *Clostridium* spp. in the in vitro fermentation tests. Catechins have also been found to increase the variety of gut microbiota and reduce the ratio of *Firmicutes*/*Bacteroidetes* in several animal studies (68, 69). Liao et al. found that tea catechins significantly increased the abundance of *Bifidobacteria* while lowering serum total cholesterol and low-density lipoprotein cholesterol levels in mice (70). Furthermore, dietary catechins have been reported to increase the relative abundance of *Akkermansia Muciniphila* and alleviate high fat diet-induced metabolic syndrome (71).

Catechins, microbiome composition, and related health benefits

Obesity is the outcome of energy surplus and is a major risk factor for a variety of chronic diseases. As a result, implementing a nutritional intervention to avoid obesity has become a public health priority (72, 73). Studies have depicted that obese individuals have a lower gut community diversity and different microbial profile compared with their lean counterparts (74). The involvement of tea catechins in weight management has been proposed due to their beneficial effects in modulating gut microbial compositions. Hursel et al. reported that catechins may improve blood biomarkers for metabolic syndrome, such as insulin, glucose, low-density lipoprotein, which was accompanied with an altered *Firmicutes* to *Bacteroidetes* ratio (67). In rats, the
combination of catechins with a high fructose oligosaccharide (FOS) diet reduced their body weight, which was correlated with increased Parabacteroides spp., Phascolarctobacterium spp., Robinsoniella spp., Prevotella spp., and decreased Lachnospira spp., Clostridiales spp., Ruminococcus spp., Peptococcaceae spp., and Oscillospira spp. (75).

A recent study suggests that catechins may have prebiotic-like activity and therapeutic potential through modulating gut microbiota. Notably, the abundance of Bacteroides and Firmicutes in the intestinal mucosa of patients with inflammatory bowel disease (IBD) was significantly reduced after catechin administration, while the population of Proteobacteria and Actinobacteria was significantly increased (76). Therefore, understanding the underlying crosstalk mechanism may help us to further elucidate the clinical value of tea catechins in the prevention and treatment of IBDs (77).

Patients with non-alcoholic fatty liver disease (NAFLD) exhibit lower Bacteroidetes and Firmicutes abundance and lower gut microbiota diversity than healthy people. The severity of non-alcoholic steatohepatitis has been linked to changes in microbiota composition (78). Patients with cirrhosis and hepatocellular carcinoma, for example, showed higher levels of Bacteroidetes and Ruminococci and lower levels of Bifidobacterium than those with cirrhosis alone. The link between gut dysbiosis and NAFLD, as well as the fact that catechins lowered endotoxin levels in the circulating and portal circulation, highlights the preventative and therapeutic potential of catechins in restoring gut barrier integrity and reducing the hepatic and intestinal inflammation (46).

**Curcumin and gut microbiota**

**Sources and chemical structures of curcumin**

Curcumin, also known as diferuloylmethane (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), is a polyphenol representing the major curcuminoids extracted from the rhizomes of Zingiberaceae and Araceae plants. It is the main active ingredient of turmeric, a common Asian spice used as a dietary spice, food coloring, and herbal medicine (47, 79). Different biological and pharmacological aspects have sparked widespread interest in its therapeutic potential. Its bioactive constituents have recently been studied. It was reported that curcumin has showed potent functions at the cellular level via regulating numerous signaling pathways (80). Notably, an increasing number of clinical trials with regard to curcumin supplementation have been published or are presently underway, reflecting the scientific community’s growing interest in curcumin’s therapeutic potential (79, 81–84).

**Bioavailability and metabolism of curcumin**

Because of the poor solubility, low bioavailability, chemical instability, and rapid metabolism, curcumin’s therapeutic potential is severely limited (85, 86). Curcumin undergoes substantial metabolism (reduction, sulfation, and glucuronidation) in liver, kidney, and intestinal mucosa after oral administration (87). Liver is the major site where the metabolism of curcumin occurs, whereas intestine and gut bacteria also play an important role in facilitating this process. In hepatocytes and enterocytes, the double bonds of curcumin are reduced, resulting in dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, and octahydrocurcumin (88, 89). The intestinal microflora is capable of deconjugating phase II metabolites and converting them back to phase I metabolites leading to the production of fission products (e.g., ferulic acid) that have a higher bioavailability (90).

In spite of the low digestibility in the upper gastrointestinal tract, curcumin can be fermented by gut microbiota, which potentially explains how it performs various physiological activities.

**Interactions between curcumin and gut microbiota**

Curcumin bioactivity, like that of other dietary polyphenols, is linked not only to absorption rate but also to its gut microbial digestion. Curcumin has shown preferential distribution and accumulation in the gut after oral or intraperitoneal dosing, despite its limited plasma and tissue bioavailability (79, 91). Curcumin can be transformed by human intestinal microbiota in a variety of metabolic pathways, including the production of active metabolites with local and systemic effects, but also by reducing the heptadieneone backbone and demethylation by Blautia spp (92, 93). In summary, undigested curcumin may accumulate in the gut, where upon the fermentation by microbiota, it can be converted into biologically active metabolites, which subsequently modulate the growth of gut microbiota in a selective manner (Figure 4).

**Metabolism of curcumin by gut microbiota**

Because of its formidable metabolic functions, such as the transformation of numerous compounds that reach the colon, the gut microbiota can be described as a biological reactor. Since the biotransformation of phytonutrients is achieved with the microbial enzymes produced by the gut microbiota, the
efficiency of curcumin biotransformation differs by microbial profile (84, 94).

Curcumin can be modified in the colon tract by a specific microorganism, Escherichia coli. Curcumin/dihydrocurcumin reductase (CurA) is a nicotinamide adenine dinucleotide phosphate (NADPH)-dependent enzyme that converts curcumin to the intermediate product dihydrocurcumin and then to the final product tetrahydrocurcumin. By reductive disruption of the chromophoric diarylheptatrienone chain in the first process of the reaction, dihydrocurcumin is produced from curcumin. The mechanism for converting dihydrocurcumin to tetrahydrocurcumin is the same in the second step (95).

Multiple gut bacteria are involved in curcumin metabolism, among which the Firmicutes Blautia spp. produces two derivatives, demethylcurcumin and bisdesmethylcurcumin, through demethylation (92). While Escherichia fergusonii and Escherichia coli strains are involved in the metabolic processes that produce dihydrocurcumin, tetrahydrocurcumin, and ferulic acid (82). Other microorganisms capable of degrading curcumin include Bifidobacterium longum, Bifidobacterium pseudostrandum, Enterococcus faecalis, Lactobacillus acidophilus, and Lactobacillus casei. Microbial metabolism of curcumin by Pichia anomala or a bacterial strain of Bacillus megaterium has been reported to produce new metabolites via various metabolic processes such as hydroxylation, demethylation, reduction, and demethoxylation. An ultra-performance liquid chromatography analysis identified 23 metabolites and discovered several novel human gut microbiota-curcumin metabolic pathways (96).

Interestingly, curcumin metabolites have been shown to have an equivalent or stronger potency compared with the parent compound. Tetrahydrocurcumin, for example, outperforms curcumin as a free-radical quencher which has shown therapeutic effects in alleviating neurodegenerative diseases (97).

**Modulation of gut microbiota by curcumin**

Since a majority of curcumin escapes the upper gastrointestinal digestion and reach the colon, it may exert
pharmacological effects by altering the richness, diversity, and composition of gut microbiota (98). A previous study found that curcumin-treated patients had a 69% increase in bacterial species, whereas an overall 15% decrease in bacterial species was observed in the control group. Participants who responded to the treatment had consistent increases in Bacteroides spp., Clostridium spp., Citrobacter spp., Enterobacter spp., Enterococcus spp., Klebsiella spp., and Pseudomonas spp., as well as decreased relative abundance in several Blautia spp. Curcumin increased the abundance of Bifidobacteria, Lactobacilli, and butyrate-producing bacteria while decreasing Prevotellaceae, Coriobacteriales, Enterobacteriaceae, and Enterococci, resulting in a significant shift in the beneficial-pathogenic microbiota ratio. Aside from anti-inflammatory and anti-colonotropic carcinogenicity activities, changes in gut microbiota may partially explain how curcumin regulates immune responses and mitigate hyperlipidemia (93).

By using a mouse model of acute myeloid, Liu et al. revealed significant changes in gut microbiota composition by intravenous curcumin administration. Specifically, they observed a significant increase in Lactobacillus acidophilus, Bifidobacterium bifidum and Lactobacillus reuteri, and decrease in pathological bacteria including Bacteroides fragilis, Escherichia coli, Fusobacterium nucleatum and Akkermansia in the interventional group, which was associated with a reduced disease severity (99). In rats, curcumin lowered the Firmicutes/Bacteroidetes ratio and reversed the high fat diet-induced gut dysbiosis, which was related to a decreased hepatic ectopic fat deposition, reduced inflammatory markers, and enhanced intestinal barrier integrity, suggesting that it could be a novel therapeutic strategy for NAFLD (100).

**Curcumin, microbiome composition, and related health benefits**

Changes in the microbiome have been linked to a variety of metabolic diseases, including obesity, diabetes, and chronic liver disease (101). In a rat model of menopause, Zhang et al. investigated the relationship between curcumin intake and gut microbial diversity, and reported that curcumin might partially repair the changes in the richness and composition of the rat gut microbiota caused by ovariectomy-induced estrogen shortage (102). In specific, curcumin increased the abundance of Serratia, Shewanella, Pseudomonas, Papillibacter, and Exiguobacterium species, while lowered that of Anaerotruncus and Helicobacter pylori (80).

Curcumin has shown neuroprotective properties by targeting the gut-brain axis and reducing intestinal inflammation through various molecular mechanisms (103–105). Studies have revealed a close association between gastrointestinal dysfunction and the exacerbation of neurological disorders. For example, the most important non-neurological complications of Huntington’s disease are associated with gastrointestinal defects. Two studies depicted that the patients with symptomatic Huntington’s disease exhibited serum metabolic shifts that suggested changes in gut microbial-derived metabolites (106, 107). Additionally, a study examined at how curcumin interacted with the gut microbiota of APP/PS1 double transgenic mice from two perspectives. Curcumin administration improved spatial learning and memory abilities in these mice while also lowered amyloid plaque burden in the hippocampus. Interestingly, curcumin administration significantly altered the relative abundances of bacterial taxa such as Bacteroidaceae, Prevotellaceae, Lactobacillaceae, and Rikenellaceae at the family level, and Prevotella, Bacteroides, and Parabacteroides at the genus level, several of which have been reported to be key bacterial species associated with Alzheimer’s disease (AD) development. It is important to note that, the gut microbiota of AD mice produced a total of 8 curcumin metabolites, and many of these metabolites have been shown to have neuroprotective properties (108).

Xu et al. used next-generation sequencing technology to investigate the effects of curcumin on gut microbiota in a rat model of uric acid nephropathy (UAN). As a result, they found that in the interventional group, renal pathological lesions were reduced, and the serum uric acid and metabolic endotoxemia were decreased, which were tightly connected with a suppressed proliferation of opportunistic pathogens such as Escherichia coli and Bacteroides, and increased relative abundance of bacteria that produce short-chain fatty acids (SCFAs), such as Lactobacillus and Ruminococcaceae (109). In a clinical trial, curcumin supplementation for 6 months restored the α-diversity of gut microbiota to a normal value in the patients diagnosed with chronic renal disease (CKD). At the phylum level, curcumin supplementation significantly inhibited the growth of Escherichia Shigella, but enhanced that of Lachnoclostridium. Moreover, compared to the baseline levels, Lactobacillaceae spp. were found to be considerably higher at the family level in the last 3 months of supplementation. No adverse events were reported in the supplemented group, suggesting a high safety profile of curcumin phytosome after long-term dosing (110).

Colorectal cancer (CAC) progression is also influenced by gut bacterial profile. In an IL-10 knockout CAC mouse model, a curcumin-rich diet significantly improved survival, reduced colon weight/length ratio, and eradicated total tumor burden. Such beneficial effects were associated with an enhanced bacterial diversity, mitigated age-related decreases in alpha diversity, a raised Lactobacillales relative abundance, and a decreased Coriobacteriales composition. Therefore, the anti-tumorigenesis properties of curcumin were linked to the maintenance of a more diversified colonic microbial ecology (111).
Anthocyanins are a class of flavonoids found in nature as pigments in a wide range of plant food. It is abundant in many berry varieties, including blackberries, blueberries, and cranberries. Their color changes depending on the pH of the food matrix and may appear purple, red, or blue. Anthocyanins contain a phenolic structure that contributes to their biological effects. Pelargonidin, cyanidin, delphinidin, peanidin, petunidin, and malvain are common anthocyanins that occur naturally in food categories (Figure 5) (112, 113). Anthocyanins have been linked to a variety of positive health outcomes, including improved blood vessel function, cancer prevention, and bone health. Since anthocyanins are naturally present in dietary sources, their use in the prevention and treatment of adverse health events is of interest, and anthocyanins may provide a safe, inexpensive, and low-risk approach to disease prevention (114–116).

Bioavailability and metabolism of anthocyanins

The bioavailability of anthocyanins can be defined as the fraction of anthocyanins that are absorbed and utilized by the body. The bioavailability of natural anthocyanins has been estimated to be as low as 2% (117). During metabolism, only a small fraction of anthocyanins are absorbed by the gastrointestinal tract and then transferred to various bodily tissues such as the kidney and liver. Meanwhile, considerable amounts of anthocyanins bypass the small intestine and enter the colon, where they are hydrolyzed and fermented by the microbiota for further digestion (118, 119). The resulting colonic metabolites of anthocyanins are transported to the liver to be further metabolized and subsequently distributed to the circulating system to achieve various biological effects.

Interactions between anthocyanins and gut microbiota

Anthocyanin-rich diets may impact the composition of the gut microbiota, which acts as a modulator for anthocyanin-related health benefits. The metabolites of major anthocyanins have been shown to improve overall gut integrity by decreasing inflammation and oxidative stress (120). The interactions between anthocyanins and gut microbiota are important factors to be considered to understand the biological activities of anthocyanins for their corresponding health benefits. The interlinkage between anthocyanin biotransformation to potentially more bioactive, low molecular weight metabolites and anthocyanin-mediated modification of gut microbiota composition contributes to favorable health outcomes (121).

Metabolism of anthocyanins by gut microbiota

With a small number of dietary anthocyanins are directly absorbed, the majority of the ingested compounds reach the colon. Bifidobacterium spp. and Lactobacillus spp. are two major families of gut bacteria that have glucosidase activities. They can metabolize phenolic substances during growth, providing energy to foster the growth of other gut bacteria. These bacterial groups have been linked to positive effects in the large intestine, such as the antibacterial action of pathogenic microorganisms through the generation of short-chain fatty acids and competition for growth substrate and adhesion sites (112).

In vitro studies conducted by Tian et al. showed that the bacterial metabolism of anthocyanins involves glycosidic linkage cleavage, anthocyanidin heterocycle breakdown, and degradation into phloroglucinol derivatives and benzoic acids (122). Anthocyanins and metabolites produced in the intestine simultaneously have the potential to selectively stimulate or hinder certain bacterial growth. Different metabolites may be formed via anthocyanin fermentation depending on the bacterial composition. The maximum conversions of anthocyanins by probiotic bacteria have been recorded, with L.
plantarum and S. thermophiles degrading cyanidin-3-glucoside and cyanidin-3-rutinoside, respectively (123). Microbial fermentation of anthocyanins and the catabolism of those compounds at various stages along the process may produce a wide range of chemicals, resulting in a highly dynamic profile of some molecules.

Modulation of gut microbiota by anthocyanins

The colonization of the gut microbiota can be altered by anthocyanin ingestion, influencing intestinal bacterial proliferation. Bifidobacterium, Lactobacillus, and Akkermansia are among these bacteria that can benefit the host, and they can catalyze anthocyanins alongside Bacteroides and Eubacterium (124). These bacteria have been linked to beneficial effects in the large intestine, including the antimicrobial effect of pathogenic bacteria by producing short chain fatty acids and competing for growth substrate and adhesion sites, but they also reduce potentially harmful bacteria, such as Clostridium histolyticum, which has been linked to tumor promotion and inflammatory bowel disease (125).

In the mice with colon cancer, oral administration of bilberry anthocyanin extract (BAE) enriched the diversity of bacterial populations in the digestive system and increased the abundance of Clostridium and Lactobacillus johnsonii. Meanwhile, the improvement of gut microbiota with daily BAE supplementation has been shown to reduce tumor growth and improve PD-L1 treatment efficacy (126). Faria et al. reported that in vitro incubation of malvidin-3-glucoside with fecal slurry increased the growth of Bifidobacterium spp. and Lactobacillus spp., but had no effect on the growth of Bacteroides spp. Surprisingly, adding malvidin-3-glucoside to other anthocyanins displayed a synergistic effect on bacterial growth. Gallic acid, an anthocyanin metabolite found in the gut, has been shown to reduce the abundance of potentially harmful bacteria including Clostridium histolyticum without affecting healthy bacteria (112).

Anthocyanins, microbiota composition, and related health benefits

It has been shown that anthocyanins are able to prevent or delay the onset of certain diseases with their anti-inflammatory
and antioxidative properties (127). Phenolic chemicals have the capacity of blocking pro-inflammatory mediators and thereby reducing inflammation. Anthocyanin metabolites have been shown to activate Nrf2, which activates the antioxidant enzymes and antioxidation-related pathways. They may also lower intestinal inflammation by modulating the MAKP and NF-B pathways mediated by TAK1 and SphK/S1P (113). Hidalgo et al. portrayed that a mixture of anthocyanins enhanced the growth of Bifidobacterium and Lactobacillus-Enterococcus in a batch culture fermentation system resembling the human distal large intestine, and interestingly, the microbial metabolite malvidin-3-glucoside alone displayed the similar beneficial effects compared with its parent compounds (128).

In a study by Liu et al. oral administration of anthocyanins in the C57BL/6J mice significantly reduced high fat diet-induced body weight gain by 20–27%, total adipose tissue weight by 18–25%, and plasma total cholesterol by 25%. Meanwhile, they observed a significantly reduced plasma lipopolysaccharide concentration, which was correlated with decreased relative abundances of Rikenella and Rikenellaceae. At the genus level, dietary supplementation of berry anthocyanin extract enhanced the growth of the groups of Lachnoclostridium, Roseburia, and Clostridium innocuum, resulting in increased fecal short chain fatty acid (SCFA) release (129). Consistently, two studies found that anthocyanins might be able to alleviate high fat diet-induced dysbiosis by reducing Luminococcus (129) and Muribaculaceae (130), while enriching Oscillo bacter (129).

Anthocyanins may prevent neurodegenerative illnesses by modulating the microbiome in the gut. Marques et al. explored into this association in rats fed a high fat diet, which is known to contribute to obesity-related neuroinflammatory and neurobehavioral abnormalities via altering the gut flora. Increased Oscillo bacter were discovered in the gut of the animals treated with the anthocyanin-rich blackberry extract. They came to the conclusion that anthocyanin regulation in the gut is linked to anti-neuroinflammatory properties by lowering TCK-1 expression, and that anthocyanins might affect the central nervous system by altering tryptophan metabolism in the kynurenine pathway, thereby increasing the production of neuroprotective metabolites and reducing systemic inflammation (130).

Khan et al. recently shown that anthocyanins can lower the expression of proinflammatory cytokines, preventing against the pathogenesis of neuroinflammation and Alzheimer’s disease (131, 132). Furthermore, anthocyanin has been shown to protect against Alzheimer’s disease and synapsis-related functions in A1-42-injected mice (133). By blocking α-amylase, anthocyanins may limit starch digestion. When this undigested starch enters the large intestine, it feeds probiotic bacteria like Lactobacilli, Bifidobacteria, and Streptococci, allowing them to continue to boost health (134).

---

Quercetin and gut microbiota

Sources and chemical structures of quercetins

Quercetin, a polyphenolic flavonoid, is abundantly present in onions, kale, apples, cherries, and red wine. Quercetin binds to sugar moieties like rhamnose or rutose in nature by attaching a sugar group as a substitute for one of the OH groups, forming quercetin glycosides and rutin (135). The sugar groups linked to quercetin can change its solubility, bioavailability, and bioactivities (136). Quercetin’s antioxidative properties are essential in the prevention and treatment of illnesses. Different pharmacological benefits of quercetin in treating osteoporosis, blood pressure, cancer, and cardiovascular disease have been described in animal and human research (136, 137) (Figure 6).

Bioavailability and metabolism of quercetins

Based on human studies, oral quercetin is primarily administered as a purified aglycone supplement. The typical daily consumption of quercetin in China, the United States, and Europe is 6–18 mg (54, 135). The bioavailability of quercetin after a single oral administration was found to be relatively low in human pharmacokinetic trials. In healthy people, the absorption rate of quercetin glucoside (the natural form of quercetin) varies between 3 and 17% per mg. Limited absorption, extensive metabolism, and/or quick excretion may all contribute to quercetin’s low bioavailability (136).

Quercetin metabolism occurs primarily in the liver. After absorption, quercetin is transported to the liver, where it undergoes phase I and phase II metabolism, producing metabolites that circulate in the blood for distribution to body tissues (138). To fully understand the concentration of quercetin in plasma following repeated administration of quercetin-rich meals, Mullen et al. evaluated the accumulation of quercetin conjugates in human plasma after feeding the subjects with onions on a regular basis. The participants consumed about 100 mg of quercetin each meal from onion slices over three meals for a week. Results showed that fasting plasma levels of glucuronide and sulfate metabolites in participants increased from 0.04 to 0.63 μM. The primary plasma metabolites quercetin-3-sulfate and 3-glucuronide reached their peak levels after half an hour. Furthermore, after 4 h, the major urine metabolites quercetin-diglucuronide, 3-glucuronide, isorhamnetin-3-glucuronide, and sulfate-glucuronide all peaked (139). Compounds that were not absorbed in the small intestine escaped to the large intestine, where colonic microbiota degraded the quercetin into phenolic acid compounds that were easily absorbed and delivered to the liver via the portal vein (140).
Interactions between quercetins and gut microbiota

In the intestine, quercetin is metabolized by resident microbiota, and the resulting products may have different biological activities compared with the parent compound. Reciprocally, quercetin may alter the microbiota's composition, which is one of the proposed mechanisms of actions for these chemicals. Through promoting beneficial flora and inhibiting potentially pathogenic flora, quercetin can therapeutically target gut microbiota and produce beneficial health consequences for the human host (141).

Metabolism of quercetins by gut microbiota

In the intestine, quercetin is converted by the microbiota to 3,4-dihydroxyphenylactic acid, also known as 3-(3-hydroxyphenyl) propionic acid, 3,4-dihydroxybenzoic acid, and 4-hydroxybenzoic acid. Bacteroides fragilis, Clostridium perfringens, Streptococcus, Lactobacillus, Bifidobacterium, and Eubacterium cladobacterium have been identified as the strains that convert quercetin to the compounds indicated above (54, 142). Jaganath et al. analyzed the microbial metabolites of quercetin 3-O-rutin and suggested that they might enhance the overall antioxidant capacity of the colon following ingestion of quercetin-rich food (143).

Modulation of gut microbiota by quercetins

Quercetin has a significant impact on the gut environment, which in turn has an impact on the regulation of gut microbiota. Food-pathogenic bacteria such as Staphylococcus aureus, Escherichia coli, Listeria monocytogenes, and Vibrio parahaemolyticus, as well as clinically important hospital or community-associated pathogens, may be present in the human gut microbiota. With the prebiotic and antibacterial effects, quercetin may diminish these pathogenic microbiota (144–146).

Lan et al. discovered that quercetin treatment improved the diversity of gut microbiota, and the major changes in the gut microbiota (Clostridium, Bacteroides, and Bacilli) were observed at the class level. After quercetin treatment, there was an increase in Lactobacillus and a decrease in Ruminococcus (144). Meanwhile, Shi et al. discovered that quercetin supplementation improved the diversity of the gut bacterial community in antibiotic-treated mice. This was accompanied with an increase intestinal barrier function, as the researchers observed a decreased serum D-lactic acid concentration and serum diamine oxidase activity. Intestinal villi length and mucosal thickness were both increased considerably after quercetin supplementation. In addition, quercetin promoted rebuilding of mice's gut microbiota following antibiotic therapy and might be used as a prebiotic in the fight against gut dysbiosis (147).

Quercetin, microbiome composition, and related health benefits

By using a mouse model of atherosclerosis and feeding the mice with quercetin for 12 weeks, researchers found that quercetin could prevent damaged arteries caused by a high fat diet, which was associated with significantly altered Bacteroidetes, Firmicutes, and Proteobacteria as well as increased Phascolarctobacterium and Anaerovibrio (148). Nie et al. found that in mice fed with a high fat diet for 12 weeks, oral quercetin supplementation significantly enhanced the immune/inflammatory responses and alleviated oxidative stress. Microbial analysis performed at the phylum level reported that quercetin treatment decreased the abundance of Verrocomicrobia, while increased the diversity of the microbiota and the abundance of Actinobacteria, Cyanobacteria, and Firmicutes. In addition, quercetin decreased gut cholesterol, lysophosphatidic acid, and atherogenic lysophosphatidylcholine levels, while increased faeprostanol levels (149).

Additionally, Lan et al. studied the effect of quercetin in alleviating osteoarthritis in a rats, and found that the quercetin supplementation reversed osteoarthritis-associated dysbiosis and changed the microbial metabolites. These studies suggested that quercetin might be used as a potential therapeutic approach in alleviating various diseases by modulating gut microbiota (144).

Chlorogenic acid and gut microbiota

Sources and chemical structures of chlorogenic acid

Chlorogenic acid (CGA), one of the most common polyphenols in the human diet, is present in a variety of fruits, vegetables, and herbs, including apples, coffee beans, tea, and wormwood plants, and has a number of health-promoting qualities (150, 151). Chlorogenic acid belongs to the hydroxycinnamic acid family of phenolic compounds. With a caffeic acid (CA) and a quinic acid (QA) moiety, it is also known as 5-O-cafeoylquinic acid (5-CQA) (Figure 7) (152). Chlorogenic acid has shown several beneficial effects with its anti-oxidative, anti-inflammatory, anti-cancer and anti-neurodegenerative activities (150).
Bioavailability and metabolism of chlorogenic acid

The hydrophilic characteristic of chlorogenic acid prevents it from passing through lipophilic membrane barriers after oral administration, resulting in limited absorption and bioavailability (153). It has been well-documented that chlorogenic acid is accessible and processed differently in the gastrointestinal tract, liver, and kidney in humans. In general, the metabolic pathways of chlorogenic acid are as follows: (I) in humans, around one-third of the chlorogenic acid in food is absorbed intact and enters the bloodstream without being hydrolyzed in the stomach and/or upper gastrointestinal tract; (II) a small amount of chlorogenic acid (about 7%) is absorbed throughout the small intestine, including hydrolysis to caffeic and quinic acid; (III) colonic microbiota-mediated metabolism of chlorogenic acid and absorption of metabolites; and (IV) intact chlorogenic acid and its metabolites are absorbed and/or metabolized in the liver (7, 154). Experiments in rat models have shown that chlorogenic acid is rarely hydrolyzed in the stomach and has no significant bioavailability before reaching the colon (155). Most chlorogenic acids are transferred to the large intestine and become small molecules with higher biological activities through the decomposition and metabolism by intestinal flora.

Interactions between chlorogenic acid and gut microbiota

Chlorogenic acid is formed from the esterification of caffeic acid and quinic acid and is often referred to as a “non-polysaccharide” based prebiotic. Only a small fraction of ingested chlorogenic acid is absorbed by the small intestine, while the majority is metabolized in the large intestine where it is extensively degraded by the gut microbiota. The gut microbiota can break down chlorogenic acid into a series of low-molecular-weight aromatic acid metabolites, including metacoumaric acid and derivatives of phenylpropionic acid and benzoic acid, which may be the main molecules responsible for its biological activity. For example, benzoic acid may support gut health by modulating gut microbiota (156–158).

Metabolism of chlorogenic acid by gut microbiota

The colon’s resident microflora could quickly hydrolyze chlorogenic acid, and the resultant products could be further metabolized by the hosts’ enzymes to produce additional metabolites that are then released to the circulating systems. When espresso coffee was cultivated with human stool samples for 6 h, it was discovered that the colonic microbiota swiftly decomposed all of the coffee chlorogenic acids, resulting in a total of 11 catabolites (155).

Tomas-Barberan et al. conducted resting cell studies on nine different colonic populations to investigate the biotransformation of caffeoylquinic acid by diverse human colonic microbiota. Before hydrolyzing their ester linkages, different bacterial communities can hydrogenate, dehydroxylate, or eliminate the quinic acid moiety. All conversion pathways focus on 3-(3-hydroxyphenyl)-propionic acid (HPPA), which is the final metabolite in most samples. The transformation rate of caffeoylquinic acid was increased under the action of Bifidobacterium animalis subsp. lactis (159).

It has also been reported that nearly 30% of ingested 5-CQA is hydrolyzed to caffeic acid and quinic acid in the rat cecum (7). These findings are in line with the in vitro evidence that human fecal bacteria at least partially hydrolyze 5-CQA.

Modulation of gut microbiota by chlorogenic acid

Chlorogenic acid may regulate the relative abundances of some essential microbial species (e.g., Burkholderiales, Desulfovibrio, Klebsiella, Desulfovibrionales, and Bifidobacterium, among others), which consequently benefit the host (155).

An in vitro study showed that chlorogenic acid significantly increased the abundance of beneficial bacteria such as the Bifidobacterium spp and the Clostridium cocoides-Eubacterium rectale group (153). Chen et al. discovered that chlorogenic acid treatment greatly enhanced the abundance of the phylum Firmicutes, adding to our knowledge of the favorable effects of dietary chlorogenic acid on improving nutrient bioavailability (158). Meanwhile, dietary chlorogenic acid supplementation reduced Bacteroides abundance in ileal samples from weaned pigs, while Bacteroides are gram-negative obligate anaerobic bacteria that have deleterious effects on the gut (156). Another
study conducted by Ludwig et al. showed that the abundance of bacteria from the phylum *Proteobacteria* in the cecal samples of the chlorogenic acid group was significantly lowered. This is important because most bacteria in the *Proteobacteria* phylum have been shown to cause long-term intestinal inflammation and injury in both neonates and adults (160).

Chlorogenic acid, microbiome composition, and related health benefits

Chlorogenic acid, as well as its metabolites caffeic acid and ferulic acid, are potent antioxidants. One study by Ding et al. demonstrated that chlorogenic acid could efficiently ameliorate cadmium-induced kidney and liver damage. Oral chlorogenic acid supplementation significantly enhanced the abundance of *Bikenella* and other anti-inflammatory bacteria, lowering cadmium poisoning symptoms (161). Ye et al. investigated the role of gut microbiota in the protection of obesity and metabolic endotoxemia by supplementing C57BL/6 mice with chlorogenic acid. As a result, chlorogenic acid altered the gut microbiota's composition by increasing the abundance of SCFA-producing bacteria (e.g., *Dubosiella*, *Romboutsia*, *Mucispirillum*, and *Faecalibaculum*) and *Akkermansia*, which was correlated with enhanced intestinal barrier. Furthermore, animals with a microbiota that was modified by chlorogenic acid had reduced body weight and fat content, as well as developed less metabolic endotoxemia (162).

Another study by Wang et al. found that administering chlorogenic acid for 6 weeks reduced body weight, improved plasma lipids linked with high fat diet-induced obesity, and modulated lipogenesis and adipogenesis gene expressions in the epididymal white adipose tissue (163). Furthermore, chlorogenic acid treatment significantly decreased *Desulfovibrio*, *Erysipelas*, *Lachnospira*, and *Ruminococcus*, as well as increased *Bacteroidetes* and *Lactobacillus*, which was associated with a decreased obesity severity. Shi et al. aimed to investigate the effect of chlorogenic acid on high fat diet-induced mouse model of non-alcoholic fatty liver disease (164), and reported that chlorogenic acid could reduce high fat diet-induced hepatic steatosis and inflammation, lower serum transaminases, and improve insulin sensitivity. Simultaneously, chlorogenic acid increased the *Bifidobacteria* content while decreased the *Escherichia coli* content in feces. These findings suggest that chlorogenic acid, through its capacity for modulating gut microbiota, may protect against high fat diet-induced hepatic steatosis and inflammation.

Bhandarkar et al. hypothesized that chlorogenic acid could improve cardiovascular, hepatic, and metabolic responses in a high carbohydrate, high fat diet-induced rat model of metabolic syndrome. Energy intake and food absorption efficiency were reduced in rats with chlorogenic acid supplementation, resulting in a reduction in visceral fat. With these, chlorogenic acid may improve the overall metabolism by regulating the diversity and profile of gut microbiota. Thus, long-term dietary chlorogenic acid reduces diet-induced inflammation as well as cardiovascular, hepatic, and metabolic changes, indicating the potential for further clinical studies of chlorogenic acid (165). However, there is a lack of well-designed clinical trials that validated the efficacy of chloric acid in improving metabolic health.

Current research and limitation

Phytonutrients modulate the gut microbiota through multiple mechanisms. These pathways may act independently or in crosstalk (Figure 8, Supplementary Table 1). Taken together, the mechanisms by which phytonutrients interact with gut microbiota in and turn affect human health include (I) direct or indirect regulation on the composition of the gut microbiota, which has an impact on the brain-gut-microbiota axis and other processes, (II) metabolism by gut microbiota, which enhances bioavailability and bioactivity of the phytonutrients, and (III) synergistic activities of different types of phytonutrients.

By reviewing the roles and mechanisms of the representative phytonutrients above, we conclude that the interactions between phytonutrients and gut microbiota may confer multiple benefits to human health (Table 1). However, various factors continue to obstruct phytonutrient function, including phytonutrient bioavailability, the composition of the gut microbiota, and the processes through which the gut microbiota influences the human body.

The physiochemical parameters that affect bioavailability of phytonutrients include the chemical class, polarity, molecular weight, structure of the phytonutrients, the activity of gastrointestinal enzyme, and the enterocyte absorption (177). Administering phytonutrients by modifying them into appropriate dosage forms would be a strategy to improve the efficiency of phytonutrient metabolism and absorption. Chen et al. proposed the use of novel nano-formulation techniques to target delivery of these phytonutrients. The cumulative transport and bioavailability of nano-EGCG was about twice of free EGCG, and the dose advantage of nano-EGCG to induce apoptosis in prostate cancer cells was more than ten times (178).

In addition, the bioavailability of most phytonutrients depends on the microbes in the gut. By regulating the abundance and quantity of gut microbiota, the bioavailability of phytonutrients can be effectively improved. For example, when mice were fed with a diet rich in pectin-rutin, bacterial abundances in *Bacteroidetes*, *Clostridium*, *Eubacteria*, *Enterobacteriaceae*, *Lactobacillus*, and *Streptococcus* were significantly increased, and plasma quercetin level was also increased (179). Meanwhile, dietary phytonutrients were metabolized by gut microbiota to form beneficial short-chain
fatty acids, which might differentially affect phytochemical bioavailability by modulating gut microbiota.

Furthermore, while earlier research has explored the impact of phytonutrients on gut microbial composition, little is known about the synergic effects of intestinal epithelial integrity and microbiota in regulating the bioavailability and bioactivity of phytonutrients. Additionally, most research focused on fecal samples, which may not accurately reflect the entire small intestinal or cecal microbiome. In order to better depict the dynamic changes of the gut microbiota and the intestine, an appropriate animal model can be established for research. For instance, Sun et al. investigated the interaction of curcumin with gut microbiota in APP/PS1 double transgenic mice for the treatment of Alzheimer's disease. The findings suggested that curcumin could affect the diversity of the gut microbiota, and a range of metabolites were bio-transformed by the gut microbiota, which would provide insights into the treatment of Alzheimer's disease (108). By addressing these questions, we will have a clear understanding of the relationship between phytonutrients and gut microbiota, as well as the mechanism by which gut microbiota acts on human body, which will guide the use of phytonutrients in the future.

**Conclusion and prospects**

Phytonutrients, as a class of nutritional supplements that can be obtained from the daily diet, enter the body through oral absorption, produce biologically active substances during metabolism in the body, and regulate the abundance and composition of intestinal flora. In this review, we focus on phytonutrients, including catechins, curcumin, anthocyanins, quercetin, and chlorogenic acid, to discuss their sources, bioavailability, interaction with gut microbiota, and their
TABLE 1  Effect of phytonutrients on gut microbiota modulation and their major effects on human health.

| Phytonutrient | Source | Type of study | Change to microbiome | Outcome of benefit | References |
|---------------|--------|---------------|-----------------------|--------------------|------------|
| Catechins     | Tea, cacao, apples, berries, grapes | Fermentation in vitro, in vivo animal study | (+) Bifidobacteria, Prevotella, Clostridium butylicum, Eubacterium Clostridium | Alleviate inflammation, resist microbial invasion, regulate immunity, protect the nervous system, protect circulatory system and cardiac tissues | (70, 166) |
| EGCG          | Green tea | In vitro assay in bacterial medium, in vivo animal and human study | (+) Bacteroides, Christensenellaceae, Bifidobacterium | Prevent GMD, suppress obesity, modulates gut microbiota, alleviate low-grade inflammation | (167–169) |
| Polyphenol    | Green tea | In vivo animal study and human study | (+) Firmicutes and Bacteroidetes | Reduce weight, promote energy conversion, reduce the levels of glucose, triglycerides and total cholesterol | (170, 171) |
| Curcumin      | Turmeric | Pilot study in humans | (-) Clostridium Bacteroides Citrobacter Cronobacter Enterobacter Enterococcus Klebsiella | Resistance to inflammation, neurotrophic effects, restore normal gut microbial diversity | (93) |
| Anthocyanins  | Cranberry, grape | In vitro (batch culture fermentation) | (-) Bacteroides, Prevotella, Blautia, Lactobacillus, Bifidobacterium, Enterobacteriaceae, Ruminococcus | Control blood sugar, reduce insulin resistance, reduce inflammation | (172) |
| Quercetin     | Green tea, lettuce, cranberry, apple, onion | In vivo animal and human study | (-) Firmicutes, Erysipelotrichia and Bacillus genus, Bacillus, Eubacterium cylindroides, Erysipelotrichaceae | Reduce inflammation, reduce insulin resistance | (173, 174) |
| Quercetin     | Onions, tea, lettuce, broccoli, apples | In vitro (human feces) | (-) Escherichia coli, Streptococcus, Lactobacillus, Enterococcos gilvus, Clostridium perfingens, Bacteroides fragilis, Lactobacillus acidophilus | Converted to beneficial metabolites by C. perfringens and B. fragilis | (142) |
| Chlorogenic acid | Certain fruits, vegetables | In vivo animal model | (+) Bifidobacterium, Dubosella, Romboutsia, Mucispirillum, Fusiformibacillus, Akkermansia | Reduce oxidative stress, reduce inflammation, reduce acute lung injury, protect cardiovascular | (162, 164) |
| Coffee and Caffeic acid | Green and roasted coffee beans, or red wine | In vivo animal and human study | (+) Bifidobacterium spp. | Prevention of colon cancer metastasis, inhibit tumor cell transformation | (175, 176) |

impacts on human health. Although the recent two decades witnessed an increasing interest in the studies of phytonutrients and microbiota, the research on the interaction between phytonutrients and gut microbiota is still in its infancy. In the foreseeable future, phytonutrients may be applied to pregnant women to maintain gut health, promote neurodevelopment, and benefit overall wellness of the infant. At the same time, the application of phytonutrients in the formation of intestinal flora in children can help mitigate adverse conditions such as inflammation in body, thereby enabling health promotion at the adolescent stage. In addition, phytonutrients may be used to improve sub-health status in adults, and daily supplementation of corresponding phytonutrients may have preventive and therapeutic effects. Although phytonutrients have shown various beneficial effects, more studies are warranted to explore how gut microbiota may enhance these bioactivities, as well as the

Frontiers in Nutrition
interaction between phytonutrients and gut microbiota. It would also be intriguing to explore unknown potential beneficial effects of phytonutrients and their microbial metabolites in the prevention and/or mitigation of diseases.

**Author contributions**

YY and JD designed the manuscript. FWa, JZ, and YL performed the literature review. FWu and JK drafted the manuscript. JK and JC revised the manuscript. All authors contributed to the article and approved the submitted version.

**Conflict of interest**

Authors JK, FWa, JZ, and JD are employees of Nutrilite Health Institute, a division of Amway. Authors FWu and YL are employed by Sequanta Technologies Co., Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.960309/full#supplementary-material
25. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. (2003) 43:89–143. doi: 10.1080/104083903902466464

26. Duda-Chodak A, Tarko T, Satora P, Sroka P. Interaction of dietary compounds, especially polyphenols, with the intestinal microbiota: a review. Eur J Nutr. (2015) 54:325–41. doi: 10.1007/s00394-015-0852-y

27. Gwiazdowska D, Jus K, Jansowska-Malecka J, Klucznyska K. The impact of polyphenols on bifidobacterium growth. Acta Biochim Pol. (2015) 62:895–901. doi: 10.18380/abp.2015.1154

28. Jin JS, Tsyoomaya M, Hisada T, Benno Y. Effects of green tea consumption on human fecal microbiota with special reference to bifidobacterium species. Microb Immunol. (2012) 56:279–39. doi: 10.1144/2012.M0052.x

29. Koutsou A, Lima M, Contriero L, Gasperotti M, Bianchi M, Fava F, et al. Effects of commercial apple varieties on human gut microbiota composition and metabolic output using an in vitro colonic model. Nutrients. (2017) 9:533. doi: 10.3390/nu9050533

30. Huang F, Zheng X, Ma X, Jiang R, Zhou W, Zhou S, et al. Thebrowham from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nutr Commun. (2019) 10.1097/10.1088/I41467-019-12896.x

31. Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. (2014) 2:187–95. doi: 10.1016/j.redox.2013.12.022

32. Wu J, Wei Z, Cheng P, Qian C, Xu F, Yang Y, et al. Rhein modulates host purine metabolism in intestine through gut microbiota and amelorates experimental colitis. Theranostics. (2020) DOI: 10.1006/j.tn.0402.3336

33. Agrigman G, Yu KB, Hsiao EY. Signaling inflammation across the gut-brain axis. Science. (2021) 374:1087–92. doi: 10.1126/science.abi6087

34. Ohno M, Nishida A, Sugitani Y, Nishino K, Inatomi O, Sugimoto M, et al. Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS ONE. (2012) 7:e018599. doi: 10.1371/journal.pone.0185999

35. Zia A, Farkhondeh T, Pourbagher-Shahri AM, Samarghandian S. The role of curcumin in aging and senescence: molecular mechanisms. Biomed Pharmacother. (2017) 134:111119. doi: 10.1016/j.biopha.2020.111119

36. Lee YM, Yoon Y, Yoon H, Park HM, Song S, Yeum KJ. Dietary anthocyanins against obesity and inflammation. Nutrients. (2017) 9:1089. doi: 10.3390/nu9101089

37. Andres S, Perry S, Ziegler C, Bakhsh A, Keene H-I, Ernst-KLI, et al. Safety aspects of the use of curcumin as a dietary supplement. Mol Nutr Food Res. (2018) 62:1780447. doi: 10.1002/mnfr.201707847

38. Eid HM, Haddad PS. The antiobstructive potential of curcumin: underlying mechanisms. Curr Med Chem. (2017) 24:355–64. doi: 10.2174/09298677323661099153707

39. Nambari SF, Tejada S, Setzer WN, Gortzi O, Sureda A, Braidy N, et al. Chlorogenic acid and mental diseases: from chemistry to medicine. Curr Nutraceut Pharm. (2017) 15:471–9. doi: 10.2174/1570159X15666106325062

40. Luca SV, Macovei I, Bujor A, Miron A, Skalicka-Wozniak K, Apolosoaie AC, et al. Addressing the inter-individual variability in response to dietary polyphenols: from isolated cultures to omic approaches. Food Funct. (2017) 8:399–412. doi: 10.1039/c6fo01233e

41. Li Q, Van de Wiele T. Gut microbiota as a driver of the interindividual variability of cardiometabolic effects from tea polyphenols. Crit Rev Food Sci Nutr. (2021) 1:13–27. doi: 10.1080/10408398.2021.1965536

42. Pastoriza S, Messias M, Cabrera C, Ruhan-Henaes JA. Healthy properties of green and white teas: an update. Food Funct. (2020) 12:650–62. doi: 10.1039/C7FO00661J

43. Actis-Goreta L, Leveque A, Reim T, Teml A, Schafer C, Hofmann U, et al. Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr. (2013) 98:924–33. doi: 10.3945/ajcn.113.106578

44. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science. (2006) 312:1353–9. doi: 10.1126/science.1114234

45. van Duynhoven J, Vaughan EE, Jacobs DM, Kemperman RA, van Velzen EL, Gross G, et al. Metabolic fate of polyphenols in the human supramicroorganism. Proc Natl Acad Sci USA. (2011) 108(Suppl. 1):4531–8. doi: 10.1073/pnas.1006918107

46. Chen W, Zhu X, Liu L, Wang X, Liu R. C-ring cleavage metabolites of catechin and epicatechin enhanced antioxidant activities through intestinal microbiota. Food Res Int. (2020) 135:109271. doi: 10.1016/j.foodres.2020.109271

47. Espin JC, Gonzalez-Sarrias A, Tomas-Barberan FA. The gut microbiota: a key factor in the therapeutic effects of polyphenols. Biochem Pharmacol. (2017) 139:92–93. doi: 10.1016/j.bcp.2017.04.033

48. Chen H, Sang S. Biotransformation of tea polyphenols by gut microbiota. J Funct Foods. (2014) 7:26–42. doi: 10.1016/j.jff.2014.01.013

49. Duenas M, Cueva C, Munoz-Gonzalez I, Jimenez-Giron A, Sanchez-Patan F, Santos-Buelga C, et al. Studies on modulation of gut microbiota by wine polyphenols: from isolated cultures to omic approaches. Antioxidants. (2015) 4:21–39. doi: 10.3390/antioxid4010001

50. Kutschera M, Engst W, Blaut M, Braune A. Isolation of catechin- and epicatechin- containing chitosomes: design, in-vitro appraisal and in-vivo studies. Int J Pharm. (2019) 565:488–98. doi: 10.1016/j.ijpharm.2019.05.034

51. Cai ZY, Li XM, Liang JP, Xiang LP, Wang KR, Shi YL, et al. Bioavailability of tea catechins and its improvement. Molecules. (2018) 23:2346. doi: 10.3390/molecules23092346

52. Liu Z, Bruins ME, Ni L, Vincken JP. Green and black tea phenolics: bioavailability, transformation by colonic microbiota, and modulation of colonic microbiota. J Agric Food Chem. (2018) 66:8469–77. doi: 10.1021/acs.jafc.8b02233

53. Santangelo R, Silvestri A, Mancuso C, Ginesiosandi, catechins, curcumin and gut microbiota: current evidence of challenging interactions. Food Chem Toxicol. (2019) 123:42–89. doi: 10.1016/j.fct.2018.10.042

54. Liu Q, Van de Wiele T. Gut microbiota as a driver of the interindividual variability of cardiometabolic effects from tea polyphenols. Crit Rev Food Sci Nutr. (2021) 1:13–27. doi: 10.1080/10408398.2021.1965536

55. Li Q, Van de Wiele T. Gut microbiota and disease. Trends Food Sci Technol. (2014) 31:267–71. doi: 10.1016/B978-0-12-398456-2.00021-9

56. Pastoriza S, Messias M, Cabrera C, Ruhan-Henaes JA. Healthy properties of green and white teas: an update. Food Funct. (2020) 11:2671–81. doi: 10.1039/C9FD00206F

57. Kan et al. Frontiers in Nutrition. 2022:38. doi: 10.3390/ijms10093009

58. Kong et al. Frontiers in Nutrition. 2022:38. doi: 10.3390/ijms10093009
microbiota of high fat diet-induced obesity mice model. Food Res Int. (2017) 92:9–16. doi: 10.1016/j.foodres.2016.12.008

70. Liao ZL, Zeng BH, Wang W, Li GH, Wu F, Wang L, et al. Impact of the consumption of tea polyphenols on early atherosclerotic lesion formation and intestinal bifidobacteria in high-fat-fed ApoE(-/-) mice. Front Nutr. (2016) 3:42. doi: 10.3389/fnut.2016.00042

71. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, et al. Dietary polyphenols promote growth of the gut bacterium akkermansia muciniphila and attenuate high-fat diet-induced metabolic syndrome. Diabetes. (2015) 64:2847–58. doi: 10.2337/db14-1916

72. Karri S, Sharma S, Hatware K, Patil K. Natural anti-obesity agents and their therapeutic role in management of obesity: a future trend perspective. Biomed Pharmacother. (2019) 110:224–38. doi: 10.1016/j.biopha.2018.11.076

73. Kan J, Ni J, Xue K, Wang F, Zheng J, Cheng J, et al. Personalized nutrition intervention improves health status in overweight/obese chinese adults: a randomized controlled trial. Front Nutr. (2022) 9:919882. doi: 10.3389/fnut.2022.919882

74. Sirotkin AV, Kolesovara A. The anti-obesity and health-promoting effects of tea and coffee. Physiol Res. (2021) 70:161–168. doi: 10.3354/physiolres.934674

75. Luo J, Han L, Liu L, Gao L, Xue B, Wang Y, et al. Catechin supplemented in a FOS diet induces weight loss by alteringecal microbiota and gene expression of colonic epithelial cells. Food Funct. (2018) 9:2962–9. doi: 10.1039/C8FO00355B

76. Barnett MP, Cooney JM, Dommeles YE, Nones K, Brewster DT, Park Z, et al. Modulation of colonic SCFAs in Mdr1a(-/-) mice by green tea polyphenols and their effects on the colon transcriptome and proteome. J Nutr Biochem. (2013) 24:1678–90. doi: 10.1016/j.jnutbio.2013.02.007

77. Guo T, Song D, Cheng L, Zhang X. Interactions of tea catechins with intestinal microbiota and their implication for human health. Food Sci Biotechnol. (2019) 28:1617–25. doi: 10.1007/s10068-019-00656-y

78. Li CC, Liu C, Fu M, Hu KQ, Aizawa K, Takahashi S, et al. Tomato powder inhibits hepatic steatosis and inflammation poten tally through restoring sirt1 activity and adiponectin function independent of carotenoid cleavage enzymes in mice. Mol Nutr Food Res. (2018) 62:e1700738. doi: 10.1002/mnfr.201700738

79. Shen L, Ji HF. Bidirectional interactions between dietary curcumin and gut microbiota. Crit Rev Food Sci Food Saf. (2019) 59:2896–902. doi: 10.1080/10408398.2018.1478838

80. Jabczyk M, Nowak J, Hudzik B, Zabelewicz-Szkodzinska B. Curcumin and its potential impact on microbiota. Nutrients. (2021) 13:2004. doi: 10.3390/nu13062004

81. Shabbir U, Rubah M, Triygi A, Oh DH. Curcumin and its derivatives as theranostic agents in alzheimer's disease: the implication of nano technology. Int J Mol Sci. (2020) 22:196. doi: 10.3390/ijms2201196

82. Tan S, Rupasinghe TW, Tull DL, Boughton B, Oliver C, McSweeney C, et al. Degradation of curcuminoids by in vitro pure culture fermentation. J Agric Food Chem. (2014) 62:11005–15. doi: 10.1021/jf5031168

83. Nisani M, Yilmaz S, Ertekin T, Ceylan D, Inanc, N, Al C, Ulger H. Effects of curcumin on lipid peroxidation and antioxidant enzymes in kidney, liver, brain and testis of mice bearing ehrlich solid tumor. In: Proceedings of the 2nd International Conference on Natural Products for Cancer Prevention and Therapy (Kayseri, Turkey). (2017). doi: 10.3390/proceedings20090994

84. Di Meo F, Margarucci S, Galderisi U, Crispi S, Peluso G. Curcumin, gut microbiota, and neuroprotection. Nutrients. (2019) 11:2426. doi: 10.3390/nu11092426

85. Adiwijaya J, McLachlan AJ, Rody AV. Curcumin as a clinically promising anti-cancer agent: pharmacokinetics and drug interactions. Expert Opin Drug Metab Toxicol. (2017) 13:953–72. doi: 10.1517/17425525.2017.1360279

86. Kumar A, Ajuha A, Ali J, Rabotta S. Conundrum and therapeutic potential of curcumin in drug delivery. Crit Rev Ther Drug Carrier Syst. (2010) 27:279–312. doi: 10.1615/CritRevTherDrugCarrierSyst.v27.i4.10

87. Paulraj F, Ahas F, Lajis NH, Othman I, Naidu R. Molecular pathways modulated by curcumin analogue, diarylpropenoids in cancer. Biomolecules. (2019) 9:270. doi: 10.3390/biom9070270

88. Pandey A, Chaturvedi A, Bhasin S, Thomas B, Gevorkian S, Malarick K, et al. A systems-level "misunderstanding" the plasma metabolome in Huntington’s disease. Ann Clin Transl Neurol. (2015) 2:576–68. doi: 10.1002/acn3.214

89. van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates DP, et al. Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis. (2011) 44:1–8. doi: 10.1016/j.nbd.2011.05.006

90. Rosas HD, Doros G, Bhainsi S, Thomas B, Revkovan S, Malarick K, et al. A systems-level "misunderstanding" the plasma metabolome in Huntington’s disease. Am J Clin Transl Res. (2015) 2:576–68. doi: 10.1002/acn3.214

91. Xia X, Wang H, Guo D, Man X, Liu L, Li J, et al. Curcumin modulates gut microbiota and improves renal function in rats with uric acid nephropathy. Ren Fail. (2021) 43:1963–75. doi: 10.1080/0886022X.2021.1944879

92. Pirvai E, Mingione A, Pazzigni G, Cecconari C, Ottaviano E, Brasacchio C, et al. Curcumin supplementation [Meriva®] modulates inflammation, lipid peroxidation and gut microbiota composition in chronic kidney disease. Nutrients. (2022) 14:2431. doi: 10.3390/nu14102431

93. McFadden RM, Larmier CR, Shehab KW, Midura-Kiea M, Ramalingam R, Harrison CA, et al. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis. (2015) 21:2483–9. doi: 10.1097/MIB.0000000000000522
hormone induced depression-like behavior. Food Funct. (2019) 10:2947–57. doi: 10.1039/C8FF02599A

156. Chen J, Yu B, Chen D, Zheng P, Luo Y, Huang Z, et al. Changes of porcine gut microbiota in response to dietary chlorogenic acid supplementation. Appl Microbiol Biotechnol. (2019) 103:8157–68. doi: 10.1007/s00253-019-10025-8

157. Chen JL, Zheng P, Zhang C, Yu B, He J, Yu J, et al. Benzoic acid beneficially affects growth performance of weaned pigs which was associated with changes in gut bacterial populations, morphology indices and growth factor gene expression. J Anim Physiol Anim Nutr. (2017) 101:1137–46. doi: 10.1111/jpn.12627

158. Chen L, Li Y, Yu B, Chen D, Mao X, Zheng P, et al. Dietary chlorogenic acid improves growth performance of weaned pigs through maintaining antioxidant capacity and intestinal digestion and absorption function. J Anim Sci. (2018) 96:1108–18. doi: 10.1093/jacskf079

159. Tomas-Barberan F, Garcia-Villalba R, Quartieri A, Raimondi S, Amaretti A, Leonardì A, et al. In vitro transformation of chlorogenic acid by human gut microbiota. Mol Nutr Food Res. (2014) 58:1122–31. doi: 10.1002/mnr.201300441

160. Ludwig IA, Paz de Pena M, Concepcion C, Alan C. Catabolism of coffee chlorogenic acid by human colonic microbiota. Biofactors. (2013) 39:623–32. doi: 10.1002/biof.1124

161. Ding Y, Li X, Liu Y, Wang S, Cheng D. Protection mechanisms underlying oral administration of chlorogenic acid against cadmium-induced hepatoxic injury related to regulating intestinal flora balance. J Agric Food Chem. (2021) 69:1675–83. doi: 10.1021/acs.jafc.0c06698

162. Ye X, Liu Y, Hu J, Gao Y, Yu M, Wen D. Chlorogenic acid-induced gut microbiota improves metabolic endotoxemia. Front Endocrinol. (2021) 12:762691. doi: 10.3389/fendo.2021.762691

163. Wang Z, Lam KL, Hu J, Ge S, Zhou A, Zheng B, et al. Chlorogenic acid alleviates obesity and modulates gut microbiota in high-fat-fed mice. Food Sci Nutr. (2019) 7:579–88. doi: 10.1002/fsn3.869

164. Shi A, Li T, Zheng Y, Song Y, Wang H, Wang N, et al. Chlorogenic acid improves NAFLD by regulating gut microbiota and GLP-1. J Nutr Biochem. (2019) 65:34–46. doi: 10.1016/j.jnutbio.2018.11.016

165. Chen T, Liu AB, Sun S, Ajiami NJ, Ross MC, Wang H, et al. Green tea polyphenols modify the gut microbiome in db/db mice as co-abundance groups correlating with the blood glucose lowering effect. Mol Nutr Food Res. (2019) 63:e1801064. doi: 10.1002/mnr.201801064

166. Zhou J, Tang L, Shen CL, Wang JS. Green tea polyphenols boost gut microbiota-dependent mitochondrial TCA and urea cycles in sprague-dawley rats. J Nutr Biochem. (2020) 81:108395. doi: 10.1016/j.jnutbio.2020.108395

167. Hester SN, Mastaloudis A, Gray R, Antony JM, Evans M, Wood SM. Efficacy of an anthocyanin and prebiotic blend on intestinal environment in obese male and female subjects. J Nutr Metab. (2018) 2017:7497260. doi: 10.1155/2017/7497260

168. Remely M, Ferk F, Sterner S, Setayesh T, Roth S, Kepcija T, et al. EGCG prevents high fat-diet-induced changes in gut microbiota, decreases of DNA strand breaks, and changes in expression and DNA methylation of Dnmt1 and MLH1 in C57BL/6 male mice. Oxid Med Cell Longev. (2017) 2017:3079148. doi: 10.1155/2017/3079148

169. Ushiroda C, Naito Y, Takagi T, Uchiyama K, Mizushima K, Higashimura Y, et al. Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice. J Clin Biochem Nutr. (2019) 69:1675–83. doi: 10.3164/jcbn.18-116

170. Chen J, Tang L, Shen CL, Wang JS. Green tea polyphenols boost gut microbiota-dependent mitochondrial TCA and urea cycles in sprague-dawley rats. J Nutr Biochem. (2020) 81:108395. doi: 10.1016/j.jnutbio.2020.108395

171. Tamura M, Hoshi C, Kobori M, Takahashi S, Tomita J, Nishimura M, et al. Quercetin metabolism by fecal microbiota from healthy elderly human subjects. PLoS ONE. (2017) 12:e0188271. doi: 10.1371/journal.pone.0188271

172. Kang NJ, Lee KW, Kim BH, Bode AM, Lee HJ, Heo YS, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MER and TOPK. Carcinogenesis. (2011) 32:921–8. doi: 10.1093/carcin/bgr022

173. Shin HS, Satsu H, Bae MJ, Zhao Z, Ogihara W, Totsuka M, et al. Anti-inflammatory effect of chlorogenic acid on the IL-8 production in Caco-2 cells and the dextran sulphate sodium-induced colitis symptoms in C57BL/6 mice. Food Chem. (2015) 168:167–75. doi: 10.1016/j.foodchem.2014.06.100

174. Osdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. Nutrients. (2016) 8:78. doi: 10.3390/nu8020078

175. Chen X, McClements DJ, Wang J, Zou L, Deng S, Liu W, et al. Coencapsulation of (-)-Epigallocatechin-3-gallate and quercetin in particle-stabilized w/o/w emulsion gels: controlled release and bioaccessibility. J Agric Food Chem. (2018) 66:3691–9. doi: 10.1021/acs.jafc.8b03516

176. Tamura M, Nakagawa H, Tsushima T, Hiraizumi K, Ishik K. Effect of pectin enhancement on plasma quercetin and fecal flora in rumin-supplemented mice. J Food Sci. (2007) 72:5648–51. doi: 10.1111/j.1750-3841.2007.00557.x